Influence of Diabetes on Tramadol Pharmacokinetics
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study aimed to investigate the influence of uncontrolled type 1 and type 2 diabetes
mellitus (DM) on the kinetic disposition, metabolism and pharmacokinetics-pharmacodynamics of
tramadol enantiomers in patients with neuropathic pain. Thus, nondiabetic patients (control
group, n = 12), patients with type 1 DM (n = 9), and patients with type 2 DM (n = 9), all
with neuropathic pain and phenotyped as extensive metabolizers of cytochrome P450 2D6
(CYP2D6) who were treated with a single oral dose of 100 mg racemic tramadol were
investigated.
Phase:
Phase 4
Details
Lead Sponsor:
Universidade Estadual Paulista Júlio de Mesquita Filho